Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease

Clin Neuropharmacol. May-Jun 2004;27(3):108-10. doi: 10.1097/00002826-200405000-00003.

Abstract

The neuropeptides neurokinin B, neurotensin, and anandamide, the endogenous ligands of NK3, NT1, and CB1 receptors respectively, are known to interact with brain dopaminergic transmission. This study evaluated the effects of these three antagonists of the NK3 (SR 142801), neurotensin (SR 48692), and cannabinoid (SR 141716) receptors on the severity of motor symptoms and levodopa-induced dyskinesias after administration of a single dose of levodopa in 24 patients with Parkinson disease. In this exploratory randomized, double-blind, placebo-controlled study, at the dose used, the drugs tested were well tolerated and could not improve parkinsonian motor disability.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Antipsychotic Agents / pharmacology
  • Antipsychotic Agents / therapeutic use*
  • Cannabinoid Receptor Antagonists*
  • Double-Blind Method
  • Dyskinesia, Drug-Induced / drug therapy
  • Dyskinesia, Drug-Induced / etiology
  • Female
  • Humans
  • Levodopa
  • Male
  • Middle Aged
  • Movement Disorders / drug therapy
  • Movement Disorders / etiology
  • Neurotensin / antagonists & inhibitors*
  • Parkinson Disease / complications
  • Parkinson Disease / drug therapy*
  • Piperidines / pharmacology
  • Piperidines / therapeutic use
  • Pyrazoles / pharmacology
  • Pyrazoles / therapeutic use
  • Quinolines / pharmacology
  • Quinolines / therapeutic use
  • Receptors, Neurotensin / antagonists & inhibitors*
  • Rimonabant

Substances

  • Antipsychotic Agents
  • Cannabinoid Receptor Antagonists
  • Piperidines
  • Pyrazoles
  • Quinolines
  • Receptors, Neurotensin
  • SR 48692
  • Neurotensin
  • Levodopa
  • SR 142801
  • Rimonabant